The COMP360 readout drives a violent CMPS repricing (≥20% intraday move) with post-readout downgrades if durability disappoints.

If the two-dose psilocybin trial results disappoint — meaning the treatment doesn't last as long as hoped — COMPASS stock could drop by 20% or more in a single trading session. Financial analysts who cover the company would likely downgrade their recommendation, telling investors to reduce or sell their position. For a company whose entire value is built on this one treatment approach, a weak result could be devastating.

Consensus of 2 agents: investor, maps_researcher. 1 dissenting.